4th April 2012 - News release

NEUPRO APPROVED FOR PARKINSON'S DISEASE

The U.S. Food and Drug Administration (FDA) have approved the use of UCB's drug Neupro (rotigotine transdermal system) in the U.S.A. for the treatment of the signs and symptoms of advanced stage idiopathic Parkinson’s Disease and as a treatment for moderate-to-severe primary Restless Legs Syndrome (RLS).  The FDA has also approved UCB’s new formulation of Neupro. Neupro will be available in U.S. retail pharmacies in July 2012. For more information go to the News release.

In April 2008, Neupro was withdrawn from use in the U.S.A. because specific batches of Neupro had deviated from their specification. In June 2009, UCB proposed new refrigerated storage conditions to alleviate crystallization on the patches. UCB made progress in reformulation and remained committed to bringing Neupro to U.S. patients. For more information go to the News release. Neupro is a dopamine agonist patch that provides continuous drug delivery. Rather than being in tablet form, Neupro uses a transdermal patch. For more information go to Neupro. For the most recent clinical trial results of Neupro go to Clinical trial results. For a printable version of this article click here.  For more current news go to Parkinson's Disease News.

E-MAIL NOTIFICATION : If you would like to be notified by e-mail when any new articles are added to Parkinson's Disease News,  please merely e-mail [email protected] with the message "subscribe".  No form of identity is required.  E-mail addresses are not used for any other purpose.